Core Insights - The U.S. naloxone market has annual sales of approximately $154 million, with a unit volume of 9.3 million units, indicating a significant and growing market opportunity for naloxone products [4]. Company Overview - Scienture Holdings, Inc. is a holding company focused on developing, commercializing, and distributing novel specialty pharmaceutical products to address unmet market needs [1][10]. - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, has entered into an agreement with Summit Biosciences for the exclusive U.S. commercialization rights to REZENOPY, a naloxone HCl nasal spray [2]. Product Details - REZENOPY is the highest dosage naloxone HCl nasal spray approved by the FDA, designed to effectively combat potent opioids [4]. - The product received FDA approval on April 19, 2024, and is indicated for emergency treatment of known or suspected opioid overdose [3][6]. Intellectual Property - The U.S. Patent and Trademark Office issued U.S. Patent No. 12,514,854 B2 for REZENOPY, effective January 6, 2026, with an expiry date of February 5, 2041, providing additional intellectual property protection [1][3]. - The patent is eligible for listing in the FDA's Orange Book, which may further support the product's commercialization in the U.S. [3]. Market Strategy - The patent issuance is viewed as a critical milestone that strengthens the intellectual property supporting REZENOPY and reinforces the value of Scienture's exclusive commercialization rights [5]. - Scienture aims to leverage the growing naloxone market and strong FDA approval status to drive meaningful impact and build long-term shareholder value [5].

Core Insights - The U.S. naloxone market has annual sales of approximately $154 million, with a unit volume of 9.3 million units [3] Company Overview - Scienture Holdings, Inc. is a holding company focused on developing, commercializing, and distributing specialty pharmaceutical products to meet unmet market needs [8] - Scienture, LLC, a wholly owned subsidiary, has entered into an exclusive agreement with Summit Biosciences for the U.S. commercialization rights of REZENOPY [2][8] Product Launch - REZENOPY is a high-strength naloxone HCl nasal spray (10 mg) approved by the FDA, designed for emergency treatment of opioid overdose [3][5] - The product is expected to be ready for wholesale distribution in Q1 2026, with commercial availability anticipated in early Q2 2026 [4] Market Positioning - REZENOPY is positioned as the highest-strength naloxone available, intended for patients who may require multiple doses of lower-strength naloxone [4] - The product aims to address critical needs in overdose situations involving potent opioids [4]

Core Viewpoint - Scienture Holdings, Inc. has entered into a definitive agreement with Summit Biosciences for the exclusive U.S. rights to launch REZENOPY, a naloxone HCl nasal spray, aimed at addressing the opioid overdose crisis [1][4]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on developing and distributing novel specialty pharmaceutical products to meet unmet market needs [11]. - Scienture, LLC is a specialty pharmaceutical company with a team dedicated to bringing unique products to market [11]. Product Details - REZENOPY (naloxone HCl) Nasal Spray 10mg is the most potent version of naloxone available, designed for emergency treatment of opioid overdose [3][7]. - The product is intended for intranasal use and is supplied in a carton containing two blister packages, each with a single spray device [7]. Collaboration and Manufacturing - Kindeva Drug Delivery will manufacture and supply REZENOPY, while Scienture will own the new drug application and handle sales, marketing, and distribution in the U.S. [2]. - This collaboration is seen as a strategic step to enhance public health initiatives and improve access to life-saving interventions for those at risk of opioid overdose [4][6]. Market Context - The nasal delivery of naloxone HCl is recognized for its efficacy and ease of use, making it a vital tool for first responders and healthcare providers [5]. - According to IQVIA data, the total annual sales for naloxone in the U.S. market reached $189 million, with a unit volume of 10 million [5].